Key facts
- This page summarizes DONG-A ST CO., LTD's Form 4 filing for NeuroBo Pharmaceuticals, Inc. (MTVA).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 20 Sep 2024, 16:20.
DONG-A ST CO., LTD - 18 Sep 2024 Form 4 Insider Report for NeuroBo Pharmaceuticals, Inc. (MTVA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- MTVA
- Reported as of
- 18 Sep 2024
- Net transaction value
- -$1,526
- SEC form
- 4
- Accepted by SEC
- 20 Sep 2024, 16:20:16 UTC
- Prior SEC filing
- 10 Jul 2024
- Next SEC filing
- 20 May 2025
- Source filing
- View source filing
- Reporting owner signature
- Dong-A St Co., Ltd.; By: /s/ Jae Hun Jung, Chief Executive Officer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
DONG-A ST CO., LTD filed Form 4 for NeuroBo Pharmaceuticals, Inc. (MTVA) on 20 Sep 2024.
Change
- Previous filing in this sequence was filed on 10 Jul 2024.
- Current net transaction value: -$1,526.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NRBO
transaction
Common Stock
Sale
- Transaction value
- $1,526
- Shares
- -407
- Change %
- -0.01%
- Price
- $3.75
- Shares after
- 5,347,792
- Date
- 12 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NRBO
transaction
Derivative
Warrants to Purchase Common Stock
Purchase
- Transaction value
- Shares
- +2,544,530
- Change %
- Price
- Shares after
- 2,544,530
- Date
- 18 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,544,530
- Exercise price
- $3.93
- Footnotes
- F2, F3
NRBO
transaction
Derivative
Warrants to Purchase Common Stock
Purchase
- Transaction value
- Shares
- +3,816,795
- Change %
- Price
- Shares after
- 3,816,795
- Date
- 18 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,816,795
- Exercise price
- $3.93
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Reporting Person's sale of 407 shares of Common Stock at a price per share of $3.75 occurred on September 12, 2024.
Footnote F2
On June 13, 2024, the Issuer issued (i) Series A Warrants to purchase up to an aggregate of 2,544,530 shares of the Issuer's common stock (the "Series A Warrant Shares") and (ii) 3,816,795 Series B Warrants to purchase up to an aggregate of 3,816,795 shares of the Issuer's common stock (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants"), to the reporting person pursuant to a securities purchase agreement dated the same date (the "Purchase Agreement"), in connection with a private placement of securities by the Issuer to certain investors. The issuance of the Warrants under the Purchase Agreement was subject to stockholder approval under applicable NASDAQ rules, which was obtained at a special meeting of the Issuer's stockholders held on September 18, 2024.
Footnote F3
These warrants expire on the earlier of (i) the twelve months anniversary of September 18, 2024, and (ii) the 60th day following the date on which the Issuer publicly announce the receiving of positive Phase 1 MAD data readout for DA-1726.
Footnote F4
These warrants expire on the earlier of (i) the five years anniversary of September 18, 2024 and (ii) the six months anniversary following the date on which the Issuer publicly announce the receiving of positive Phase 1, Part 3 data readout for DA-1726.